Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins Revenue up 14% as sales momentum from Q4’20 continues Pre-clinical product revenue up 24% Operating margin significantly improves year-over-year on GAAP and adjusted basis
Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins
- Revenue up 14% as sales momentum from Q4’20 continues
- Pre-clinical product revenue up 24%
- Operating margin significantly improves year-over-year on GAAP and adjusted basis
HOLLISTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three months ended March 31, 2021.
Jim Green, Chairman and CEO said, “Our first quarter revenue reflects continuation of the sales momentum we saw in the fourth quarter last year, driven by focus on sales effectiveness, demand for our pre-clinical products and recovering academic lab sales. Q1 pre-clinical product revenue grew 24%, with strong sales of our new inhalation product. Revenue growth coupled with cost management and reduction in sales of lower value products delivered strong operating margin expansion, all while significantly bringing down our leverage ratio.”
Green concluded, “With our strong momentum and improving confidence in our business, our outlook for 2021 continues to improve. We are now expecting revenue growth of 10% to 14% for fiscal 2021 compared to 2020 and expect adjusted operating margin expansion to the mid-to-upper teens. This growth allows for disciplined reinvestment in growth initiatives to stay on track to creating the growth oriented, profitable platform we envisioned.”
| Quarterly Financial Results Summary | Q1'21 | Q1'20 | |||||||||||
| Revenue | $ | 27.0 | million | $ | 23.8 | million | |||||||
| Operating Loss (GAAP) | $ | (0.2 | ) | million | $ | (3.3 | ) | million | |||||
| Adjusted Operating Income | $ | 3.2 | million | $ | 0.5 | million | |||||||
| Operating Margin (GAAP) | (0.9 | ) | % | (13.8 | ) | % | |||||||
| Adjusted Operating Margin | 12.0 | % | 2.0 | % | |||||||||
| Loss Per Share (GAAP) | $ | (0.02 | ) | $ | (0.12 | ) | |||||||
| Adjusted Diluted Earnings (Loss) Per Share | $ | 0.05 | $ | (0.01 | ) | ||||||||
| Net Debt* | $ | 39.1 | million | $ | 44.3 | million | |||||||
| * Debt outstanding less cash and cash equivalents | |||||||||||||
Please refer to the exhibits below for a reconciliation of certain non-GAAP to GAAP financial measures, including operating income, net income and loss, and diluted earnings per share. Please see “Use of Non-GAAP Financial Information” for additional information regarding our use of such adjusted financial information.
Webcast and Conference Call Details
Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID# 5876756.
The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. A slide presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins. To listen to the webcast, log on to the webcast at: http://investor.harvardbioscience.com/ and click on the Earnings Call icon.
Use of Non-GAAP Financial Information
In this press release, we have included non-GAAP financial information including adjusted operating income, adjusted net income, and adjusted diluted earnings per share. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as amortization of intangibles related to acquisitions, costs related to acquisition, disposition and integration initiatives, impairment charges, severance, restructuring and other business transformation expenses, and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-GAAP financial information approximates information used by our management to internally evaluate the operating results of the Company. Tabular reconciliations of our adjusted operating income, adjusted net income (loss), and adjusted earnings (loss) per diluted share are included as exhibits below in this press release.
The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.
About Harvard Bioscience
Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as “will,” “guidance,” “objectives,” “optimistic,” “potential,” “future,” “expects,” “plans,” “estimates,” “continue,” “drive,” “strategy,” “potential,” “potentially,” “growth,” “long-term,” “projects,” “projected,” “intends,” “believes,” “goals,” “sees,” “seek,” “develop” “possible” “new,” “emerging,” “opportunity,” “pursue” and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company’s or management’s beliefs or expectations, the Company’s anticipated future revenues and earnings, the strength of the Company’s market position and business model, industry outlook, the impact of the COVID-19 pandemic on the Company’s business, the Company’s business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company’s current products, or products it is developing or intends to develop, and the Company’s plans, objectives and intentions that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, and in our other filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein may cause the Company’s actual results to differ materially from those in the forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. The Company’s results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
For investor inquiries, please contact Michael A. Rossi, Chief Financial Officer at (508) 893-8999.
| Exhibit 1 | ||||||||||
| HARVARD BIOSCIENCE, INC. | ||||||||||
| Consolidated Statements of Operations | ||||||||||
| (unaudited, in thousands, except per share data) | ||||||||||
| Three Months Ended | ||||||||||
| March 31, 2021 | March 31, 2020 | |||||||||
| Revenues | $ | 26,989 | $ | 23,771 | ||||||
| Cost of revenues | 11,558 | 10,789 | ||||||||
| Gross profit | 15,431 | 12,982 | ||||||||
| Operating expenses: | ||||||||||
| Sales and marketing expenses | 5,386 | 5,579 | ||||||||
| General and administrative expenses | 6,333 | 6,759 | ||||||||
| Research and development expenses | 2,487 | 2,490 | ||||||||
| Amortization of intangible assets | 1,464 | 1,427 | ||||||||
| Total operating expenses | 15,670 | 16,255 | ||||||||
| Operating loss | (239 | ) | (3,273 | ) | ||||||
| Other expense: | ||||||||||
| Interest expense | (411 | ) | (1,299 | ) | ||||||
| Other (expense) income, net | (34 | ) | 111 | |||||||
| Total other expense | (445 | ) | (1,188 | ) | ||||||
| Loss before income taxes | (684 | ) | (4,461 | ) | ||||||
| Income tax (benefit) expense | (15 | ) | 55 | |||||||
| Net loss | $ | (669 | ) | $ | (4,516 | ) | ||||
| Loss per common share: | ||||||||||
| Basic and diluted | $ | (0.02 | ) | $ | (0.12 | ) | ||||
| Weighted-average common shares: | ||||||||||
| Basic and diluted | 39,787 | 38,329 | ||||||||
| Exhibit 2 | ||||||||||
| HARVARD BIOSCIENCE, INC. | ||||||||||
| Condensed Consolidated Balance Sheets | ||||||||||
| (unaudited, in thousands) | ||||||||||
| March 31, 2021 | December 31, 2020 | |||||||||
| Assets | ||||||||||
| Cash and cash equivalents | $ | 5,815 | $ | 8,317 | ||||||
| Accounts receivables | 17,074 | 17,766 | ||||||||
| Inventories | 22,676 | 22,262 | ||||||||
| Other current assets | 3,658 | 3,355 | ||||||||
| Total current assets | 49,223 | 51,700 | ||||||||
| Property, plant and equipment | 3,699 | 3,960 | ||||||||
| Goodwill and other intangibles | 90,107 | 91,741 | ||||||||
| Other long-term assets | 8,220 | 8,853 | ||||||||
| Total assets | $ | 151,249 | $ | 156,254 | ||||||
| Liabilities and Stockholders’ Equity | ||||||||||
| Current portion, long-term debt | $ | 1,970 | $ | 1,721 | ||||||
| Other current liabilities | 18,748 | 19,332 | ||||||||
| Total current liabilities | 20,718 | 21,053 | ||||||||
| Long-term debt | 41,601 | 46,286 | ||||||||
| Other long-term liabilities | 11,815 | 12,234 | ||||||||
| Stockholders’ equity | 77,115 | 76,681 | ||||||||
| Total liabilities and stockholders’ equity | $ | 151,249 | $ | 156,254 | ||||||
| Exhibit 3 | |||||||||
| HARVARD BIOSCIENCE, INC. | |||||||||
| Condensed Consolidated Statements of Cash Flows | |||||||||
| (unaudited, in thousands) | |||||||||
| Three Months Ended | |||||||||
| March 31, 2021 | March 31, 2020 | ||||||||
| Cash flows from operating activities: | |||||||||
| Net loss | $ | (669 | ) | $ | (4,516 | ) | |||
| Adjustments to operating cash flows | 2,894 | 2,640 | |||||||
| Changes in operating assets and liabilities | (1,188 | ) | 4,747 | ||||||
| Net cash provided by operating activities | 1,037 | 2,871 | |||||||
| Cash flows from investing activities: | |||||||||
| Additions to property, plant and equipment | (151 | ) | (241 | ) | |||||
| Addition to intangible assets | (150 | ) | - | ||||||
| Net cash used in investing activities | (301 | ) | (241 | ) | |||||
| Cash flows from financing activities: | |||||||||
| Repayments of debt | (4,500 | ) | (4,829 | ) | |||||
| Payments of debt issuance costs | (101 | ) | - | ||||||
| Proceeds from exercise of stock options | 1,924 | - | |||||||
| Taxes paid for issuance of stock | (464 | ) | (242 | ) | |||||
| Net cash used in financing activities | (3,141 | ) | (5,071 | ) | |||||
| Effect of exchange rate changes on cash | (97 | ) | (12 | ) | |||||
| Decrease in cash and cash equivalents | (2,502 | ) | (2,453 | ) | |||||
| Cash and cash equivalents at the beginning of period | 8,317 | 8,335 | |||||||
| Cash and cash equivalents at the end of period | $ | 5,815 | $ | 5,882 | |||||
| Exhibit 4 | |||||||||
| HARVARD BIOSCIENCE, INC. | |||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) | |||||||||
| (in thousands, except per share data) | |||||||||
| Three Months Ended | |||||||||
| March 31, 2021 | March 31, 2020 | ||||||||
| GAAP operating loss | $ | (239 | ) | $ | (3,273 | ) | |||
| Stock-based compensation expense | 968 | 793 | |||||||
| Severance, restructuring and transformation costs | 985 | 1,471 | |||||||
| Acquired assets amortization and impairments | 1,513 | 1,484 | |||||||
| Adjusted operating income | $ | 3,227 | $ | 475 | |||||
| GAAP operating margin | -0.9 | % | -13.8 | % | |||||
| Adjusted operating margin | 12.0 | % | 2.0 | % | |||||
| GAAP net loss | $ | (669 | ) | $ | (4,516 | ) | |||
| Stock-based compensation expense | 968 | 793 | |||||||
| Severance, restructuring and transformation costs | 985 | 1,471 | |||||||
| Acquired assets amortization and impairments | 1,513 | 1,484 | |||||||
| Income tax (expense) benefit (A) | (744 | ) | 287 | ||||||
| Adjusted net income (loss) | $ | 2,053 | $ | (481 | ) | ||||
| GAAP loss per diluted share | $ | (0.02 | ) | $ | (0.12 | ) | |||
| Adjusted items after tax per share assuming dilution | 0.07 | 0.11 | |||||||
| Adjusted earnings (loss) per diluted share | $ | 0.05 | $ | (0.01 | ) | ||||
| Weighted average diluted common shares: | |||||||||
| GAAP | 39,787 | 38,329 | |||||||
| Adjusted | 42,109 | 38,329 | |||||||
| (A) Income taxes includes the tax effect of the adjustments to GAAP results. | |||||||||
